Reducing phlegm

"Reducing phlegm" is a therapeutic objective and clinical outcome aimed at clearing excessive or highly viscous mucus from the respiratory tract, rather than a specific molecular target such as a protein or receptor (StatPearls, 2023). This process is critical in managing obstructive pulmonary diseases where mucus hypersecretion leads to airway narrowing, impaired gas exchange, and increased susceptibility to bacterial infections (Nature Reviews Disease Primers, 2015). Pharmacological intervention typically involves mucoactive agents classified as mucolytics, which chemically degrade the structural components of mucus, or expectorants, which increase the volume and hydration of secretions to facilitate their expulsion via coughing (NIH, 2022). While not a target itself, this process involves various molecular entities, including airway mucins (MUC5AC and MUC5B) and ion channels like the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that maintain the hydration of the airway surface liquid (PubMed, 2014). Consequently, medications that "reduce phlegm" are essential for improving the quality of life and respiratory function in patients with chronic bronchitis, cystic fibrosis, and bronchiectasis.

Other names

MucolysisExpectorant actionMucus clearanceSecretolysis

Drugs facilitate phlegm reduction through several distinct mechanisms: mucolytics (e.g., N-acetylcysteine) cleave disulfide bonds between mucin polymers to reduce viscosity; expectorants (e.g., guaifenesin) stimulate the gastropulmonary vagal reflex to increase the hydration and volume of airway secretions; and mucokinetic agents (e.g., ambroxol) enhance the efficiency of the ciliary beat to improve transport (StatPearls, 2023; PMC6522338).